Laurent Vernillet

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 493 citations · Full text

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: A twenty‐eight–day, multicenter, phase II, randomized, double‐blind, placebo‐controlled, dose‐response clinical trial examining safety and efficacy in patients with gout

Michael A. Becker, H. Ralph Schumacher, Robert L. Wortmann et al. · Arthritis & Rheumatism · 2005 · 267 citations

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans.

Alexandre Santos, Sylvie Zanetta, Thierry Cresteil et al. · PubMed · 2000 · 213 citations

Metabolomic Profiling, Secondary Metabolite, Experimental Pharmacology +24

Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions.

Marie‐Christine Haaz, Laurent P. Rivory, C. Riché et al. · PubMed · 1998 · 159 citations

Chemoprevention Strategy, Human Hepatic Microsomes, Toxicological Mechanism +17

Pharmacokinetics and Pharmacodynamics of Febuxostat, a New Non-purine Selective Inhibitor of Xanthine Oxidase in Subjects with Renal Impairment

Michael D. Mayer, Reza Khosravan, Laurent Vernillet et al. · American Journal of Therapeutics · 2005 · 153 citations